Jazz Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Jazz Pharmaceuticals (Palo Alto, CA): 9 reconciled FDA prescription therapies (1.6% 2025 to 2030 cliff risk), $1.24B 2024 CMS Part D & Medicaid spend, and 22 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Palo Alto, CA |
| Reconciled FDA Portfolio Therapies | 9 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 1.6% |
| Primary Portfolio LOE Date | 2029-01-01 |
| 2024 CMS Total Public Spend | $1.24B |
| 2024 Medicare Part D Spend | $490.8M |
| 2024 Medicaid Spend | $751.7M |
| California HCAI SB 17 Filings | 22 WAC filings (max 23.7% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.